A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation

Molecular and Clinical Oncology
Antonio MatroneFrancesco Latrofa

Abstract

Absence of neoplastic disease in the organ-recipient is required in order to allow organ transplantation. Due to its rarity, no data regarding management of patients with Multiple endocrine neoplasia type 1 (MEN1) and end-stage renal failure candidates for kidney transplantation are available. A 36 year-old man was referred to the present hospital with MEN1, with a neuroendocrine pancreatic tumor and primary hyperparathyroidism and associated Alport syndrome with end stage renal failure. The present study aimed to establish the eligibility of the patient for a kidney transplantation. The neuroendocrine tumor had been treated with duodenopancreatectomy two years earlier and hyperparathyroidism by parathyroidectomy. The review of the literature did not provide data regarding the eligibility for kidney transplantation of patients harboring a neuroendocrine pancreatic tumor in the context of MEN1. Due to the end-stage renal failure, neuroendocrine markers were unreliable and the investigation therefore relied on imaging studies, which were unremarkable. Young age, low-grade tumor, low expression of Ki67, absence of metastatic lymph nodes, onset in the setting of a MEN1 were all positive prognostic factors of the neuroendocrine tumo...Continue Reading

References

Mar 1, 1974·The Journal of Clinical Investigation·G L BilbreyJ P Knochel
Mar 27, 2001·Transplantation Proceedings·J R ChapmanA P Disney
Dec 21, 2006·JAMA : the Journal of the American Medical Association·Claire M VajdicAndrew E Grulich
May 2, 2009·Journal of the American Society of Nephrology : JASN·Germaine WongJonathan C Craig
Apr 25, 2012·Journal of the National Cancer Institute·G RindiB Wiedenmann
Jan 26, 2016·Kidney International·Tilman B Drüeke, Ziad A Massy
Mar 11, 2016·The New England Journal of Medicine·Babak J OrandiDorry L Segev
Oct 6, 2016·Frontiers in Immunology·Esmaeil MortazIan M Adcock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Related Papers

RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
M HorgerK Müssig
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J T Pang, Rajesh V Thakker
© 2022 Meta ULC. All rights reserved